Early Phase Study of KESONOTIDE™in Participants With Solid Tumours

NCT06926075 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancers
Breast Cancer
Lung Cancers
Ovarian Cancer
Glioblastoma Multiforme (GBM)
Pancreas Cancer
Skin Cancer

Interventions

DRUG: A novel hGIIA-Vimentin Inhibitor
DRUG: Dose expansion

Sponsor

Filamon LTD